-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of May 28, Chenguang Biotechnology Group Co.
, Ltd.
("Chenguang Bio") issued an announcement stating that it intends to use temporarily idle raised funds of no more than 330 million yuan to temporarily supplement the liquidity required for daily operations.
The term is from this time.
No more than 12 months from the date of the resolution of the board of directors, the funds will be returned to the special account for raised funds before expiry
.
Chenguang Biology stated that in order to improve the efficiency of the use of raised funds and reduce the company’s financial costs, it plans to use the “integrated natural plant extraction system” in accordance with relevant regulations, under the premise of ensuring the capital requirements for the construction of raised capital investment projects and the normal progress of raised capital investment projects.
The “Chemical Project (Phase I)” raised funds not exceeding 330 million yuan temporarily supplement the company’s working capital
.
In December 2019, with the approval of the China Securities Regulatory Commission, Chenguang Biotechnology publicly issued convertible corporate bonds with a total face value of 630 million yuan to the public for a period of 6 years.
The raised funds are planned to be used in the "Integrated Natural Plant Extraction Project (Phase 1)" And replenish working capital
.
After deducting related expenses, the net amount of the proceeds from the issuance of convertible corporate bonds is 619 million yuan
.
According to the announcement, the funds raised from the issuance of convertible bonds plan to invest 450 million yuan in the integrated natural plant extraction and integration project (Phase I), and a total of nearly 116 million yuan has been invested; it is planned to invest 180 million yuan in supplementary working capital projects.
The accumulated investment is nearly 170 million yuan
.
It is worth noting that on July 3, 2020, the board meeting of Chenguang Biotechnology also agreed to use the "Integrated Natural Plant Extraction Project (Phase I)" to temporarily supplement working capital with raised funds of no more than 285 million yuan
.
As of May 20, 2021, the above-mentioned funds raised for temporary supplementation of working capital shall be returned to the special account for funds raised, and the use period shall not exceed 12 months
.
